The cell therapy manufacturing market is estimated to reach close to USD 11 Billion - "Roots Analysis"
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion - "Roots Analysis"
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity

Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030report to its list ofofferings.


Owing to variousreasons, the demand for cell therapies is anticipated to increase over the comingyears. Therefore, both therapy developers and contract service providers mayneed to strengthen their capabilities and expand available capacity. In thiscontext, automation is expected to be a key enabler within the cell therapymanufacturing and contract services industry.


To order this 550+ page report, which features160+ figures and 250+ tables, please visit this -


Key Market Insights


More than 160 organizationsclaim to be engaged in cell therapy manufacturing

The market landscapeis dominated by industry players, representing more than 60% of the totalnumber of stakeholders. Amongst these, over 55 are large or mid-sized firms (havingmore than 50 employees).


100+ players focused on T-cell and stem cell therapies

Most of these playersare focused on manufacturing T-cell therapies, including CART, TCR or TILs. Itis worth highlighting that more than 35 organizations claim to have necessarycapabilities for the manufacturing of both types of therapies.


Presently, 70+ companies have commercial scale capacity

As majority of the celltherapy products are in clinical trials, the demand is high at this scale. However,it is worth noting that several players (~50%) have already developedcommercial scale capacity for cell therapies.


Europe is currently considered a current hub for celltherapy production

More than 220manufacturing facilities have been established by various players, worldwide;of these, 35% are in Europe, followed by those based in North America. Otheremerging regions include Australia, China, Japan, Singapore, South Korea andIsrael.


50+ facility expansions reported between 2015-2019

More than 85% of theexpansions are related to setting up of new facilities across differentregions. Maximum expansion activity was observed in the US and in certaincountries within the Asia Pacific regions.

20+ companies offer automatedsolutions to cell therapy developers

Players that claim tooffer consultancy services related to automation include (in alphabeticalorder) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics,GE Healthcare and Terumo BCT. Further, we identified players, namely (inalphabetical order) Fraunhofer Institute for Manufacturing Engineering andAutomation IPA, Invetech, KMC Systems, Mayo Clinic Center for RegenerativeMedicine and RoosterBio, that offer consultancy solutions related toautomation.


Partnership activityhas grown at an annualized rate of 16%, between 2014 and 2018

More than 200agreements have been inked in the last 5 years; majority of these were focused onthe supply of cell-based therapy products for clinical trials. Other popular typesof collaboration models include manufacturing process development agreements (16%),services agreements (12%) and acquisitions (10%).


By 2030, developedgeographies will capture over 60% of the market share

Asia Pacific isanticipated to capture the major share (~36%) of the market by 2030. It is alsoimportant to highlight that financial resources, technical expertise and establishedinfrastructure is likely to drive cell therapy manufacturing market in Europe,which is estimated to grow at a CAGR of ~26%.



Gaurav Chaudhary

+1 (415) 800 3415